NCT06528093 2026-02-03
A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy
Boehringer Ingelheim
Phase 1 Terminated
Clinical Trials
138 trialsNCT04643405 2026-01-08
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT04203160 2025-12-31
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT06199466 2025-12-08
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT04659603 2025-10-01
CARMEN-BT01
Sanofi
Phase 2 Terminated
NCT03656536 2025-08-24
FIGHT-302
Incyte Corporation
Phase 3 Terminated
NCT02784795 2025-08-21
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT00529113 2025-05-29
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
Biogen
Phase 1 Terminated
NCT05389462 2025-05-22
A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
ADC Therapeutics S.A.
Phase 1 Terminated
NCT02047500 2025-05-11
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
ImmunoGenesis
Phase 1 Terminated
NCT01834235 2025-05-07
QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Precision Biologics, Inc
Phase 1/2 Terminated
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT05494866 2025-03-25
IntenSify
German Cancer Research Center
Phase 1 Terminated
NCT03520790 2025-03-21
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT02672917 2025-01-28
Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
BioNTech SE
Phase 1 Terminated
NCT02671890 2025-01-07
Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer
Mayo Clinic
Phase 1 Terminated
NCT02512692 2024-11-18
Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma
Medical University of South Carolina
Phase NA Terminated
NCT01318642 2024-11-08
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
NantBioScience, Inc.
Phase 2 Terminated
NCT03512756 2024-11-06
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
Tyme, Inc
Phase 2/3 Terminated
NCT04989218 2024-11-05
ICC
University of Alabama at Birmingham
Phase 1/2 Terminated
NCT04683939 2024-10-02
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
BioNTech SE
Phase 1/2 Terminated
NCT03450018 2024-05-24
SLC-0111-17-01
British Columbia Cancer Agency
Phase 1/2 Terminated
NCT03773302 2024-05-08
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
QED Therapeutics, a BridgeBio company
Phase 3 Terminated
NCT04088188 2024-05-06
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
Academic and Community Cancer Research United
Phase 1 Terminated
NCT02452970 2024-04-24
EPIC
EpicentRx, Inc.
Phase 2 Terminated
NCT03848182 2024-04-18
Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer
Albert Einstein College of Medicine
Phase 2 Terminated
NCT03519308 2024-03-15
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Terminated
NCT04046887 2024-01-05
Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
Indiana University
Phase 1 Terminated
NCT05193604 2023-12-08
A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Terminated
NCT01897454 2023-12-05
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
Albert Einstein College of Medicine
Phase 2 Terminated
NCT04066491 2023-11-14
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
EMD Serono
Phase 2/3 Terminated
NCT03649321 2023-11-09
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT00625586 2023-11-03
Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
MacroGenics
Phase 2 Terminated
NCT02383433 2023-10-23
Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT03714555 2023-10-18
Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine
HonorHealth Research Institute
Phase 2 Terminated
NCT04099888 2023-09-11
RELEASE
PCI Biotech AS
Phase 2 Terminated
NCT00658593 2023-08-04
Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer
Canadian Cancer Trials Group
Phase 3 Terminated
NCT04163900 2023-05-24
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NuCana plc
Phase 3 Terminated
NCT02393248 2023-01-06
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
Phase 1/2 Terminated
NCT04060342 2022-08-18
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Gossamer Bio Inc.
Phase 1 Terminated
NCT01525069 2022-08-10
Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
Washington University School of Medicine
Phase 1 Terminated
NCT01461915 2022-06-06
PGPC1
Jazz Pharmaceuticals
Phase 2 Terminated
NCT02514031 2022-06-03
ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1 Terminated
NCT04131192 2022-05-06
Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
Sunshine Lake Pharma Co., Ltd.
Phase 1 Terminated
NCT01198522 2022-04-15
Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients
Philogen S.p.A.
Phase 1 Terminated
NCT00447122 2022-03-08
BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
Brown University
Phase 1 Terminated
NCT01956812 2021-08-16
PANCRIT®-1
Gilead Sciences
Phase 3 Terminated
NCT01683422 2021-08-10
Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer
Loma Linda University
Phase NA Terminated
NCT03451773 2021-06-16
M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated